Biogen (BIIB) entered into a definitive agreement to acquire private biotech, HI-Bio, for a $1.15 billion upfront payment. The acquisition will expand Biogen’s rare disease pipeline by adding Hi-Bio’s lead candidate, felzartamab, a promising late-stage ready asset with potential application across a range of rare immune-mediated diseases. Felzartamab, a fully human anti-CD38 monoclonal antibody, has demonstrated an impact on key biomarkers and clinical endpoints in three renal diseases. Felzartamab is being ...